Thestra

Our diagnostic solutions provide clinicians novel tools to estimate cancer aggressivity at the time of diagnosis and help them to select the most effective, and health economical therapies. CURRENT TARGET DISEASE Head and neck squamous cell carcinoma (HNSCC) Almost one million new cases annually 50% mortality rate No improvement in survival rate over the decades Lack of diagnostic method to identify deadly cancer cases BENEFITS FOR: CLINICIANS AND HOSPITALS Novel, accurate tool for diagnosis and prognosis Facilitated decision-making Cost savings PATIENTS Less side-effects Better quality of life through accurate diagnosis and personalised treatment THESTRA SOLUTION: Patented EPLINEx™ solution for identification of HNSCC cases that are life threatening. Artificial intelligence based HNSCC tissue analysis.